Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.66 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 2/20 | 0.60 |
| ▸ | KLK7 | P49862 | 2/20 | 0.60 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5328146 | 1.00 | SIRT2 (0.66) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL2467817 | 0.99 | FOLH1 (0.65) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL699636 | 0.99 | FOLH1 (0.65) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL1491720 | 0.99 | FOLH1 (0.65) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL1021938 | 0.96 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL918813 | 0.96 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL4958981 | 0.96 | SYK (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL17039826 | 0.95 | FOLH1 (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL19952843 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 | |
| SCHEMBL19952844 | 0.95 | SIRT2 (0.60) | SIRT2SIRT1FOLH1MAPTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | SIRT2 52/4885SIRT1 34/4885FOLH1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.